Nonsteroidal progesterone receptor modulators: Structure activity relationships

Seminars in Reproductive Medicine

Volumn 23, Issue 1, 2005, Pages 46-57

  Winneker, Richard C ^a,b   Fensome, Andrew ^a   Wrobel, Jay E ^a   Zhang, Zhiming ^b   Zhang, Puwen ^a  

^a PFIZER INC   (United States)

^b Women's Health Research Institute   (United States)

Author keywords

Contraception; Endometriosis; Hormone therapy; PR agonists; PR antagonists; Progesterone receptor (PR); Uterine fibroids

Indexed keywords

ANTIGESTAGEN; BENZIMIDAZOLE 2 THIONES; BENZIMIDAZOLE DERIVATIVE; BENZOXAZINE DERIVATIVE; ESTROGEN; GESTAGEN; NONSTEROIDAL PROGESTERONE AGONIST; NONSTEROIDAL PROGESTERONE ANTAGONIST; PROGESTERONE; PROGESTERONE RECEPTOR; STEROID RECEPTOR; UNCLASSIFIED DRUG;

AGONIST; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CONTRACEPTION; DECIDUALIZATION; ENDOMETRIOSIS; ENDOMETRIUM HYPERPLASIA; FEMALE GENITAL SYSTEM; GYNECOLOGIC DISEASE; HORMONAL THERAPY; HUMAN; HYPERTROPHY; MENSTRUAL CYCLE; MONKEY; NONHUMAN; OVIDUCT; OVULATION; RABBIT; REVIEW; STRUCTURE ACTIVITY RELATION; UTERUS MYOMA; VAGINA;

ANIMALS; FEMALE; HORMONE ANTAGONISTS; HUMANS; RECEPTORS, PROGESTERONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 14744298376     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-864033     Document Type: Review

References (46)

1. Edgren RA, Sturtevant FM. Potencies of oral contraceptives. Am J Obstet Gynecol 1976;125:1029-1038
2. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545-553
3. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-1079
4. Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fractures: a metaanalysis of randomized trials. JAMA 2001;285:2891-2897
5. Vercellini P, De Giorgi O, Oldani S, et al. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 1996;175:396-401
6. Glasier A, Baird D. The effects of self-administering emergency contraception. N Engl J Med 1998;339:1-4
7. Brogden RN, Goa KL, Faulds D. Mifepristone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1993;45:384-409
8. Slayden OD, Zelinski-Wooten MB, Chwalisz K, Stouffer RL, Brenner RM. Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct. Hum Reprod 1998;13:269-277
9. Zelinski-Wooten MB, Slayden OD, Chwalisz K, et al. Chronic treatment of female rhesus monkeys with low doses of the antiprogestin ZK 137 316: establishment of a regimen that permits normal menstrual cyclicity. Hum Reprod 1998;13:259-267
10. Kettel LM, Murphy AA, Morales AJ, Yen SS. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod 1994;9(suppl 1):116-120
11. Kettel LM, Murphy AA, Morales AJ, Yen SS. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 1998;178:1151-1156
12. Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993;76:513-517
13. Brenner RM, Slayden OD, Critchley HOD. Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor. Reproduction 2002;124:167-172
14. Zhang P, Terefenko EA, Fensome A, et al. Novel 6-aryl-1,4-dihydrobenzo[d] oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists. Bioorg Med Chem Lett 2003;13:1313-1316
15. Zhang Z, Lundeen SG, Zhu Y, Carver JM, Winneker RC. In vitro characterization of trimegestone: a new potent and selective progestin. Steroids 2000;65:637-643
16. Pathirana C, Stein RB, Berger TS, et al. Nonsteroidal human progesterone receptor modulators from the marine alga Cymopolia barbata. Mol Pharmacol 1995;47:630-635
17. Zhi L, Tegley CM, Kallel EA, et al. Aryl-1,2-dihydrochromeno[3,4-f] quinolines: a novel class of nonsteroidal human progesterone receptor agonists. J Med Chem 1998;41:291-302
18. Palmer S, Campen CA, Allan GF, et al. Nonsteroidal progesterone receptor ligands with unprecedented receptor selectivity. J Steroid Biochern Mol Biol 2000;75:33-42
19. Conti CJ, Gimenez-Conti IB, Zerbe GO, Gerschenson LE. Differential effects of estradiol-17b and progesterone on the proliferation of glandular and luminal cells of rabbit uterine epithelium. Biol Reprod 1981;24:643-648
20. McPhail MK. The assay of progestin. J Physiol London 1934;83:145-156
21. Zhang Z, Funk C, Glasser SR, Mulholland J. Progesterone regulation of heparin-binding epidermal growth factor-like growth factor gene expression during sensitization and decidualization in the rat uterus: effects of the antiprogestin, ZK 98. 99. Endocrinology 1994;135:1256-1263
22. Lundeen SG, Zhang Z, Zhu Y, Carver JM, Winneker RC. Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone. J Steroid Biochem Mol Biol 2001;78:137-143
23. Van Uem JFHM, Hsiu JG, Chillik CF, et al. Contraceptive potential of RU 486 by ovulation inhibition: I. Pituitary versus ovarian action with blockade of estrogen-induced endometrial proliferation. Contraception 1989;40:171-184
24. Kloosterboer HJ, Deckers GH, de Gooyer ME, et al. Pharmacological properties of a new selective antiprogestagen: Org 33628. Ann N Y Acad Sci 1995;761:192-201
25. Kloosterboer HJ, Deckers GH, Schoonen WGEJ, et al. Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids 2000;65:733-740
26. Zhang P, Fensome A, Wrobel J, Winneker R, Zhang Z. Nonsteroidal progesterone receptor modulators. Expert Opin Ther Pat 2003;13:1839-1847
27. Zhi L, Tegley CM, Pio B, et al. Nonsteroidal progesterone receptor antagonists based on 6-thiophenylhydroquinolines. Bioorg Med Chem Lett 2000;10:415-418
28. Zhang P, Terefenko EA, Fensome A, et al. Potent nonsteroidal progesterone receptor agonists: synthesis and SAR study of 6-aryl benzoxazines. Bioorg Med Chem Lett 2002;12:787-790
29. Beck CA, Weigel NL, Moyer ML, Nordeen SK, Edwards DP. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc Natl Acad Sci USA 1993;90:4441-4445
30. Fensome A, Koko M, Wrobel J, et al. Novel 5-aryl-1,3-dihydro-indole-2- thiones: potent, orally active progesterone receptor agonists. Bioorg Med Chem Lett 2003;13:1317-1320
31. Coffins MA, Hudak V, Bender R, et al. Novel pyrrole-containing progesterone receptor modulators. Bioorg Med Chem Lett 2004;14:2185-2189
32. Zhi L, Tegley CM, Pio B, et al. Benzylidene-1,2-dihydrochromeno[3,4-f] quinolines as selective progesterone receptor modulators. J Med Chem 2003;46:4104-4112
33. Edwards JP, Zhi L, Pooley CLF, et al. Preparation, resolution, and biological evaluation of 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines: potent, orally active, nonsteroidal progesterone receptor agonists. J Med Chem 1998;41:2779-2785
34. Zhi L, Tegley CM, Edwards JP, et al. Alkyl-1,2-dihydrochromeno[3,4-f] quinolines: a novel class of nonsteroidal progesterone receptor modulators. Bioorg Med Chem Lett 1998;8:3365-3370
35. Zhi L, Tegley CM, Pio B, et al. Synthesis and biological activity of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives as progesterone receptor modulators. Bioorg Med Chem Lett 2003;13:2071-2074
36. Tabata Y, Miike N, Hatsu M, et al. PF1092A, B and C, new nonsteroidal progesterone receptor ligands produced by Penicillium oblatum. I. Taxonomy of producing strain, fermentation, isolation and biological activities. J Antibiotics 1997;50:304-308
37. Tabata Y, Iizuka Y, Shinei R, et al. CP8668, a novel orally active nonsteroidal progesterone receptor modulator with tetrahydrobenzindolone skeleton. Eur J Pharmacol 2003;461:73-78
38. Dong Y, Roberge JY, Wang Z, et al. Characterization of a new class of selective nonsteroidal progesterone receptor agonists. Steroids 2004;69:201-217
39. Pooley CLF, Edwards JP, Goldman ME, et al. Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore. J Med Chem 1998;41:3461-3466
40. Zhi L, Ringgenberg JD, Edwards JP, et al. Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore. Bioorg Med Chem Lett 2003;13:2075-2078
41. Hamann LG, Winn DT, Pooley CLF, et al. Nonsteroidal progesterone receptor antagonists based on a conformationally-restricted subseries of 6-aryl-1,2-dihydro-2,2,4-trimethylquinolines. Bioorg Med Chem Lett 1998;8:2731-2736
42. Zhang P, Terefenko EA, Wrobel J, et al. Synthesis and progesterone receptor antagonist activities of 6-aryl benzimidazolones and benzothiazolones. Bioorg Med Chem Lett 2001;11:2747-2750
43. Fensome A, Bender R, Cohen J, et al. New progesterone receptor antagonists: 3,3-disubstituted-S-aryloxindoles. Bioorg Med Chem Lett 2002;12:3487-3490
44. Zhang P, Terefenko EA, Fensome A, et al. Aryl-1,4-dihydrobenzo[d][1,3] oxazin-2-ones: a novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists. J Med Chem 2002;45:4379-4382
45. Winneker RC, Bitran D, Zhang Z. The preclinical biology of a new potent and selective progestin: trimegestone. Steroids 2003;68:915-920
46. Bitran D, Shiekh M, McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors. J Neuroendocrinol 1995;7:171-177